Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Accumulated Expenses (2017 - 2025)

UroGen Pharma (URGN) has disclosed Other Accumulated Expenses for 9 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses fell 75.67% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Dec 2025, down 75.67%, and an annual FY2025 reading of $1.9 million, down 75.67% over the prior year.
  • Other Accumulated Expenses was $1.9 million for Q4 2025 at UroGen Pharma, down from $5.0 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $7.9 million in Q4 2024 and bottomed at $288000.0 in Q1 2024.
  • Average Other Accumulated Expenses over 5 years is $2.4 million, with a median of $1.9 million recorded in 2024.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 686.15% in 2023, then plummeted 90.96% in 2024.
  • Year by year, Other Accumulated Expenses stood at $729000.0 in 2021, then tumbled by 32.65% to $491000.0 in 2022, then surged by 686.15% to $3.9 million in 2023, then soared by 105.91% to $7.9 million in 2024, then plummeted by 75.67% to $1.9 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for URGN at $1.9 million in Q4 2025, $5.0 million in Q3 2025, and $4.9 million in Q2 2025.